Moxifloxacin and Claritin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Moxifloxacin (moxifloxacin) and Claritin (loratadine). Common drug interactions include gallbladder disorder among females and hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Moxifloxacin and Claritin. It is created by eHealthMe based on reports of 58 people who take the same drugs from the FDA, and is updated regularly.

What is Moxifloxacin?

Moxifloxacin has active ingredients of moxifloxacin. eHealthMe is studying from 12,980 Moxifloxacin users. Check the latest studies of Moxifloxacin.

What is Claritin?

Claritin has active ingredients of loratadine. It is often used in allergies. eHealthMe is studying from 77,316 Claritin users. Check the latest studies of Claritin.



On Aug, 05, 2026

58 people who take Moxifloxacin and Claritin together, and have interactions are studied.

Moxifloxacin and Claritin drug interactions.

What are the common drug interactions of Moxifloxacin and Claritin, by gender? *:

female:

  1. Gallbladder disorder
  2. Hepatic lesion
  3. Hepatitis (inflammation of the liver)
  4. Hypokalaemia (low potassium)
  5. Hypophagia (reduced food intake)
  6. Hypovolaemia (a decreased volume of circulating blood in the body)
  7. Ligament sprain (ligament stretched)
  8. Limb injury
  9. Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)
  10. Mucosal ulceration (ulcers of mucous membrane)

male:

  1. Hypertension (high blood pressure)
  2. Autoimmune hepatitis
  3. Hepatitis b antibody positive
  4. Insomnia (sleeplessness)
  5. Malaise (a feeling of general discomfort or uneasiness)
  6. Muscular weakness (muscle weakness)
  7. Myalgia (muscle pain)
  8. Platelet count decreased
  9. Quality of life decreased
  10. Red blood cell count decreased

What are the common drug interactions of Moxifloxacin and Claritin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Rectal haemorrhage (bleeding from anus)

30-39:

  1. Hypertension (high blood pressure)
  2. Autoimmune hepatitis
  3. Hepatitis b antibody positive
  4. Chronic kidney disease
  5. Hepatitis (inflammation of the liver)
  6. Nephrogenic anaemia (anaemia due to kidney disease)
  7. Renal failure (kidney dysfunction)
  8. Renal injury (kidney injury)
  9. Alanine aminotransferase increased
  10. Aspartate aminotransferase increased

40-49:

  1. Headache (pain in head)
  2. Asthenia (weakness)
  3. Cough
  4. Dyspnoea (difficult or laboured respiration)
  5. Fatigue (feeling of tiredness)
  6. Hypersensitivity
  7. Abdominal discomfort
  8. Abdominal pain upper
  9. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  10. Acute respiratory distress syndrome

50-59:

  1. Nausea (feeling of having an urge to vomit)
  2. Osteonecrosis of jaw (death of bone of jaw)
  3. Pain
  4. Fatigue (feeling of tiredness)
  5. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  6. Hypoaesthesia (reduced sense of touch or sensation)
  7. Oedema peripheral (superficial swelling)
  8. Osteomyelitis (infection of bone)
  9. Asthenia (weakness)
  10. Gait disturbance

60+:

  1. Arthralgia (joint pain)
  2. Asthenia (weakness)
  3. Death
  4. Dysstasia (difficulty in standing)
  5. Heart rate irregular
  6. Insomnia (sleeplessness)
  7. Malaise (a feeling of general discomfort or uneasiness)
  8. Muscular weakness (muscle weakness)
  9. Platelet count decreased
  10. Quality of life decreased

What are the existing conditions these people have? *

  1. Neurotrophic Keratopathy (decreased corneal sensitivity and poor corneal healing): 6 people, 10.34%
  2. Metastases To Bone (cancer spreads to bone): 6 people, 10.34%
  3. Immunodeficiency Common Variable: 6 people, 10.34%
  4. Multiple Myeloma (cancer of the plasma cells): 5 people, 8.62%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 8.62%
  6. Breast Cancer: 5 people, 8.62%
  7. Bone Cancer Metastatic: 5 people, 8.62%
  8. Osteomyelitis (infection of bone): 4 people, 6.90%
  9. White Blood Cell Count Decreased: 3 people, 5.17%
  10. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 3 people, 5.17%

* Approximation only. Some reports may have incomplete information.

Do you take Moxifloxacin and Claritin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Moxifloxacin and Claritin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Moxifloxacin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Claritin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Moxifloxacin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Claritin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on moxifloxacin and loratadine (the active ingredients of Moxifloxacin and Claritin, respectively), and Moxifloxacin and Claritin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: